Progranulin Knockout Accelerates Intervertebral Disc Degeneration in Aging Mice

Yun-peng Zhao1,2, Qing-yun Tian1, Ben Liu1, Jason Cuellar1, Brendon Richbourgh1, Tang-hong Jia3 & Chuan-ju Liu1,4

1Department of Orthopaedic Surgery, New York University Medical Center, New York, NY, 10003, 2Department of Spinal Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, PR China, 3Department of Orthopaedic Surgery, Jinan Central Hospital, Shandong University, Jinan, Shandong 250012, PR China, 4Department of Cell Biology, New York University School of Medicine, New York, NY 10016.

Intervertebral disc degeneration (IVD) is a common degenerative disease, yet much is unknown about the mechanisms during its pathogenesis. Herein we investigated whether progranulin (PGRN), a chondroprotective growth factor, is associated with IVD degeneration. PGRN was detectable in both human and murine IVD. The levels of PGRN were upregulated in murine IVD tissue during aging process. Loss of PGRN resulted in an early onset of degenerative changes in the IVD tissue and altered expressions of the degeneration-associated molecules in the mouse IVD tissue. Moreover, PGRN knockout mice exhibited accelerated IVD matrix degeneration, abnormal bone formation and exaggerated bone resorption in vertebra with aging. The acceleration of IVD degeneration observed in PGRN null mice was probably due to the enhanced activation of NF-κB signaling and β-catenin signaling. Taken together, PGRN may play a critical role in homeostasis of IVD, and may serve as a potential molecular target for prevention and treatment of disc degenerative diseases.

Degenerative disc disease (DDD) is one of the most prevalent degenerative diseases in aging population in which intervertebral disc (IVD) undergoes extensive morphological as well as biomechanical changes, and usually manifests clinically in patients with lower back pain1-2. The mechanisms involved in this degenerative process have not been fully understood, and therapies are mainly palliative. A majority of the researches concerning this issue focus on: the relationship between bone quality, bone metabolism and IVD degeneration, bony tissue formation in IVD and abnormal change of trabecular bone quality in adjacent vertebra3. Moreover, cartilage degeneration is extensively investigated, because cartilage is a major structural component of normal IVD, and the loss of proteoglycan, a dominant component of cartilage, is a feature of disc degeneration4-6.

Progranulin (PGRN) is a pleiotropic growth factor with a plethora of functions. PGRN is expressed in various cells and plays a critical role in many physiological and disease processes such as: wound healing7, tumorigenesis8 and inflammation9-11. Studies have also found that low levels of PGRN can cause degenerative diseases of the nervous system in both human and mice12,13. We previously reported that PGRN was expressed in human articular cartilage, and its level was significantly elevated in cartilage of patients with osteoarthritis and rheumatoid arthritis14. In addition, PGRN also plays a crucial role in chondrocyte proliferation15, differentiation and endochondral ossification of growth plate during development16. PGRN antagonized tumor necrosis factor-ζ (TNF-ζ) through its ability to bind to TNF receptors. It was also documented that PGRN exhibits anti-inflammatory function within inflammatory arthritis models17. Recently, we found that PGRN play a critical role in maintaining homeostasis of cartilage and protect against osteoarthritis18,19. Herein we examined the expression pattern of PGRN in IVD tissue of human and mice under physiological and degenerative conditions, and determined the potential effects of PGRN deficiency on IVD degeneration as well as the alteration of signaling pathways during aging process.

Results

PGRN is expressed in both human and murine IVD tissue and its levels are elevated in murine IVD during aging. To investigate the potential involvement of PGRN in disc degeneration of human being, we examined its expression pattern in IVD tissue disc degeneration patients. Immunohistochemistry results demonstrated PGRN
was detectable in cell clusters formed in nucleus pulposus (NP) (Figure 1A, left panel), annulus fibrosus (AF) (Figure 1A, middle panel) and end plate (EP) (Figure 1A, right panel) structures of IVD. High-resolution analysis (Figure 1A, inserts) detected that in the cell clusters formed in all mentioned three parts of IVD tissue, PGRN was specifically expressed in the extracellular matrix and cytoplasm of the cell clusters, which implied a role of PGRN during the process of IVD degeneration. To investigate the expression pattern of PGRN in the mouse IVD during aging process, total IVD tissue was collected from 2- and 9-month old WT mice, and real time PCR as well as western blotting were performed (n = 3 for each group). As shown in Figure 1B and 1C, both mRNA and protein levels of PGRN were elevated in 9-month-old IVD compared with 2-month old group.

**PGRN knockout mice develop ectopic bone formation and an early onset of degeneration in IVD cartilage.** To determine the role of endogenous PGRN in maintaining integrity of IVD, we assessed the morphology of the IVD tissues from 4-, 6- and 9-month-old WT and PGRN−/− mice. At 4 months of age, early onset of degeneration was observed in the IVD tissue of PGRN−/− group. The morphology of the cartilage at this stage showed disorganization as well as newly formed bone was present in PGRN−/− mice (Figure 2A, left panels). The normal cell phenotype was replaced by degenerative chondrocyte-like cells (Figure 2A, right panels). In 6-month-old mice, new bone formation in IVD tissue was detected via micro CT and histology (Figure 2B), and 9-month-old PGRN−/− mice showed narrowing of intervertebral space together with very severe bony tissue formation in IVD (Figure 2C). Levels of osteoblastic marker genes, including alkaline phosphatase (ALP), osteocalcin, osterix, collagen I (Col I) and bone sialoprotein (BSP) were analyzed through real-time PCR (n = 3 for each group), and the result revealed that expressions of these markers were significantly higher in PGRN−/− mice in both 6- and 9-month old group (Figures 2D, 2E and 2F), which were consistent with acceleration of new bone formation during the aging process observed within these mutant mice by micro CT assay and HE staining.

To assess the loss of proteoglycan and disorder of cartilage structure in intervertebral disc, we performed Safranin O staining. In 6-month old PGRN−/− mice, loss of proteoglycan was severe in the endplate cartilage, accompanied by newly formed bone, and high-resolution analysis showed that cell clusters were formed in EP (Figure 3A). In 9-month old WT mice, loss of proteoglycan and newly formed bone were detectable in EP tissue. In 9-month old PGRN−/− mice, disorder of AF was severe with extensive loss of proteoglycan, alteration of cell type and cleft formation in addition to degeneration changes in the EP and the boundary between NP and inner AF became less clear (Figure 3B, left panel). Moreover, degenerative fibrocartilage, chondrocyte-like cells, mucous degeneration and clefts were present in NP tissue of PGRN−/− mice, which were absent in WT littermates (Figure 3B, right panel). To verify the degradation of aggrecan, immunohistochemistry for neo-epitope of aggrecan was performed in 6-month old WT and PGRN−/− mice, and dramatically stronger signal was observed in IVD of PGRN−/− mice (Figure 3C). To investigate the accelerated aggrecan degradation in IVD of PGRN−/− mice, we collected RNA from IVD of WT and PGRN−/− mice, and performed real time RT-PCR to assess level of ADAMTS-5. Figure 3D indicates that ADAMTS-5 level was dramatically elevated in PGRN−/− group compared to the WT controls, which may explain the enhanced degradation of aggrecan in PGRN−/− group. As the feature of cartilaginous structure is the proteoglycan matrix and cartilage cell, based on the Safranin O staining of intervertebral disc, percentage of cartilaginous area in IVD was assessed with histomorphometric software, and data demonstrated that although there was no statistical significance in 4-month group, in 6- and 9-month old groups PGRN−/− mice exhibited significantly lower cartilage area percentage compared with WT littermates (Figure 3E). To further confirm the degeneration of cartilage tissue in IVD, we performed real time RT-PCR (n = 3 for each group) to assess levels of Col10 and MMP13. Expressions of both Col10 and MMP13 were significantly higher.
In all three aged groups of PGRN−/− mice compared to the corresponding WT controls (Figures 3F, 3G and 3H), clearly indicating that absence of PGRN leads to accelerated cartilage degeneration.

**PGRN knockout mice display significantly higher pathological scores in the IVD tissue.** On the basis of histology, the histological grading system was used as proposed by Boos et al. According to the parameters mentioned, the scoring and statistical analysis revealed that in the EP tissue, PGRN−/− mice showed a significantly higher score as early as 4-month old in comparison of WT mice (Figure 4A). However, EP score of PGRN−/− mice underwent no significant change with aging process (4 M vs. 6 M, p = 0.7552; 6 M vs. 9 M, p = 0.8019; 6 M vs. 9 M, p = 0.7552). This may suggest that the EP tissue, PGRN−/− mice underwent no significant change in 4-month old group between genotypes. In 6- and 9-month old PGRN−/− mice, we did not observe severe degeneration in NP of both genotypes; while in 9-month old group, PGRN−/− mice exhibited degeneration of fibrocartilage, change of cell type to cartilage-like cells, mucous degeneration and cleft formation in NP, which further contributed to the difference of histological score between WT and PGRN−/− mice (Figure 4B). Then we put the scores from AF/NP and EP panel together and found consistent trend with scores respectively (Figure 4C), which suggested that absence of PGRN led to significant degeneration in IVD tissue. There was no significant difference of score between two observers.

**PGRN knockout mice display augmented osteoclastogenesis for erosion of EP and trabecular bone of vertebra.** To further study the role of PGRN in integrity of spine, we tested osteoclastogenesis in WT and PGRN−/− mice. TRAP staining of 6-month old spine showed remarkably elevated osteoclast activity within both the newly formed bone tissue (in EP cartilage) and the trabecular bone (beneath growth plate of lumbar vertebra) in PGRN−/− mice, which was not present in the WT littermates (Figure 4D). To verify the osteoclast activity in spine, we used micro CT to analyze the trabecular bone in L4 vertebra of 6-month old WT and PGRN−/− mice, and found that PGRN deficient mice exhibited lower quality of trabecular bone (Figure 4E). The parameters of trabecular bone through micro CT, bone volume/tissue volume/ (BV/TV) and thickness of trabecular bone (Th.Tb) were significantly lower in 6- and 9-month old PGRN−/− mice, which implied accelerated osteoporosis in the vertebra of these mice (Figures 4F and 4G). According to micro CT data, there was no significant difference in 4-month old group between genotypes. Then we examined the expressions of the marker genes concerning osteoclastogenesis, including TRAP and Cathepsin K through real time RT-PCR (n = 3 for each group), and found that higher level of these genes were observed in each PGRN−/− aged group (Figures 4H, 4I and 4J).

**PGRN knockout mice exhibit enhanced activation of NF-κB signaling in IVD.** Our recent finding that PGRN inhibited TNF mediated activation of NF-κB signaling pathway, together with the reports that NF-κB signaling played a critical role in IVD degeneration, promoted us to determine whether PGRN deficiency affected NF-κB signaling that in turn contributed the IVD degeneration. To investigate the alteration of NF-κB signaling expression in the absence of PGRN, NF-κB2 level was measured.
using real time RT-PCR (n = 3 for each group). As revealed by Figures 5A, 5B and 5C, NF-κB2 level was significantly higher in IVD of all three PGRN−/− aging groups. To further determine the effects of PGRN deficiency on the activation of NF-κB signaling, immunohistochemistry was performed for phosphorylation of IκB-α, an inhibitor of NF-κB activity in IVD, and 4-, 6- and 9-month old PGRN−/− mice demonstrated remarkably higher signal of pIκB-α around nuclei of cells in EP compared with WT controls (Figure 5D); in addition, total IVD extracts were collected from both WT and PGRN−/− mice and western blotting was performed. As shown in Figure 5E, the level of pIκB-α was elevated in all PGRN−/− aging groups. The combination of this experimental data show that a loss of PGRN results in augmented NF-κB signaling in IVD. Nitrous Oxide (iNOS) and interleukin-1β (IL-1β) are target genes of NF-κB signaling which have been reported to be involved in IVD degeneration23. To determine the altered expression level of iNOS in deficiency of PGRN, RNA extracts were collected from IVD of 6-month old WT and PGRN−/− mice. The RNA level of IL-1β and iNOS were measured through real time PCR (n = 3 for each group), and IVD of PGRN−/− mice showed increased level of both target genes (Fig. 5F and 5G). In addition, protein level of iNOS was evaluated through western blot analysis, and IVD of PGRN−/− mice exhibited increased iNOS expression in protein level (Fig. 5H). Collectively, these data suggest that both expression and activity of NF-κB signaling was enhanced in IVD of PGRN−/− mice.

PGRN knockout mice display increased expression of β-catenin and its downstream target genes in IVD. The fact that Wnt/β-catenin signaling pathway is another pathway known to play an important role in IVD degeneration action24; together with the recent report that loss of PGRN resulted in increased expressions of Wnt signaling molecules in neural system25,26, led us to examine whether Wnt/β-catenin signaling pathway is involved in the PGRN-deficiency mediated IVD degeneration. For this purpose we first examined the effects of PGRN deletion on β-catenin expression in IVD. Briefly, IVD from WT and PGRN−/− mice of indicated ages were harvested and total RNA and protein were extracted for real time RT-PCR and western blotting assay, respectively. As shown in Figures 6A, 6B and 6C, mRNA level of β-catenin was significantly higher in IVD of all PGRN−/− groups (n = 3 for each group). Moreover, the western blot results revealed that β-catenin protein levels are elevated in PGRN−/− mice when compared with WT groups (Figure 6D). Additionally, immunohistochemistry of β-catenin was performed in IVD of 6-month old WT and PGRN−/− mice. As shown in Figure 6E, β-catenin signal was stronger and more nuclear translocation of β-catenin was observed in IVD tissue of PGRN−/− mice. Collectively, this set of assays suggested that Wnt/β-catenin signaling pathway is probably involved in PGRN-knockout induced osteoarthritis and abnormal bone formation observed in PGRN-knockout IVDs (Figure 2). To further investigate the activity of Wnt/β-catenin signaling, expression levels of downstream target genes including Axin2 and RUNX2 in IVD of 6-month old WT and PGRN−/− mice were measured through real time RT-PCR (n = 3 for each group). Figure 6F and 6G determined that Axin2 level and RUNX2 level was significantly higher in PGRN−/− IVD, suggesting the activation of Wnt/β-catenin signaling pathway. On the basis of the present study, Figure 6H presented a proposed model for the role of PGRN in IVD degeneration. PGRN protects against IVD degeneration through at least two pathways. Firstly, PGRN inhibited NF-κB signaling pathway mediated induction of its target genes including ADAMTS (e.g. ADAMTS-5), MMPs (e.g. MMP13) and cytokines
Proteoglycan is a main constituent of cartilaginous structure including articular cartilage and IVD, and plays an indispensable role in IVD. Proteoglycan loss within the matrix is one of the universal hallmark features of disc degeneration. We observed that proteoglycan loss was dramatically exaggerated in PGRN−/− mice with aging, especially for cartilaginous EP and AF. This suggests enhanced degeneration of cartilage structure in PGRN−/− mice. One possible reason was that PGRN was protective for cartilage matrix and chondrocyte function, as PGRN was reported to promote chondrocyte proliferation, differentiation and cartilage repair in animal models. It has been well established that the degradation of aggregcan, a key matrix protein, is a parameter for IVD degeneration. Here we observed that deficiency of PGRN led to the destruction of cartilage structure and more severe degradation of aggregcan in IVD in vivo. Moreover, ADAMTS-5 level was elevated in IVD of PGRN−/− mice. ADAMTS-5 functions as an aggrecanase in mice, and plays a pivotal role in progression of IVD degeneration. By using an antibody that specifically identifies neoepitope of aggrecan degradation, we found enhanced aggrecan degradation in PGRN−/− mice. These data indicate that PGRN also plays a chondroprotective role in IVD through protecting against matrix degradation. Additionally, PGRN was known to inhibit cartilage degradation mediated by ADAMTS-7 and ADAMTS-12. Recently, it was reported that ADAMTS-7 and ADAMTS-12 are also expressed in rat IVD tissue and their levels were elevated during disc degeneration. In the current study, the expression of MMP13 was significantly higher in each group of PGRN−/− IVD tissue. MMP13 is involved in cartilage degradation and has been used as one of the markers for degeneration of both articular cartilage and IVD. Data from the murine models also revealed that suppression or inhibition of MMP13 can attenuate the degenerative process. Collagen type 10 (Col10) is a marker of bone formation in the spine, which accelerate degeneration of IVD.
for cartilage degeneration and its level was also used to monitor the severity of disc degeneration. Collectively, our data demonstrated that absence of PGRN leads to abnormal levels of degeneration-related molecules and severe loss of cartilage matrix through aging.

Extensive studies have found that aging plays a critical role in homeostasis of both articular cartilage and IVD. In the present study, we used longitudinal analysis to evaluate the degeneration of IVD during aging process. The histological grading system for mice disc degeneration mainly focuses on new bone formation and degeneration of cartilage structure. In the EP, the histological score of mutant group was significantly higher from 4-month old, but was not dramatically changed with aging. This may suggest that EP undergoes the degeneration process first and reached a high level of degeneration at relatively young age. On the other hand, the cartilage/IVD area were similar between 4-month old WT and PGRN−/− mice, this may indicate the fibrosis and bone turnover in EP at this age remain at a low level. The expression of bone markers such as ALP, osteocalcin, BSP, osterix and Col 1 were similar between 4-month old WT and PGRN−/− mice, while the expression of chondrocyte hypertrophy and osteoclast marker genes were higher in 4 month old PGRN−/− mice, the result may indicate that the aspects of degeneration did not show up parallel, the hypertrophy and osteoclastogenesis took place ahead of bone turnover. In NP and AF, however, there was remarkable change during aging for both WT and PGRN−/− mice. The result might indicate the time interval between the change of biomarkers and morphological change, which might cause the unparallel signs of degeneration in different experiments.

There is minimal blood supply to the IVD, necessitating diffusion of nutrients through the cartilaginous EP. Therefore, the intact endplate is crucial for normal function of IVD. In this study, we observed that degeneration process occurred in EP tissue as early as 4-month old in PGRN−/− mice. This change may further accelerate the degeneration of AF and NP and leads to complete disc herniation, and spondylosis, because degeneration and the newly formed bone tissue in EP would seriously affect the diffusion process of nutrient source for AF and NP. In the present study, we found that PGRN was not detectable in mice NP tissue, but 9-month old PGRN−/− mice showed more severe degeneration compared with WT littermates. This is probably because that deficiency of PGRN directly disturbs normal function of EP and AF through promoting cartilage degeneration, which subsequently resulted in nutrient limitation.
deficiency of NP. Taken together, absence of PGRN might affect homeostasis of IVD both directly and indirectly, in the course of IVD degeneration process.

With degenerated IVD from human patients, we found that while PGRN was certainly expressed in the extracellular matrix of cell clusters formed in AF and NP of disc degeneration patients, suggesting a possible role for PGRN in the IVD degeneration process. Furthermore, the level of PGRN was elevated during aging in WT mice. This is consistent with our previous report that PGRN level was dramatically higher level of expression of PGRN in IVD when compared with WT littermates suggesting the activity of a key mediator of age-dependent disc degeneration. Studies have shown that stimulation of NF-κB signaling can accelerate, while inhibition of this signaling can attenuate, disc degenerative diseases associated with aging. Phosphorylation of IκB-α is a commonly tested parameter for the activation of NF-κB signaling pathway. In our current study, we found that the level of pIκB-α was dramatically elevated in PGRN−/− IVD in each aged group. Moreover, iNOS is a target gene of NF-κB signaling pathway which controls the synthesis of NO, and is involved in IVD degeneration. In this study, iNOS was tested and PGRN−/− IVD presented higher iNOS expression both in RNA level and protein level. Collectively, these data suggested excess activation of the NF-κB signaling pathway in the absence of PGRN may lead to the accelerated IVD degeneration in aging.

The β-catenin signaling pathway has been found to play a critical role in development, metabolism and degeneration of IVD. It has been found that activation of β-catenin induces IVD degeneration. Recently, it was reported that PGRN interacts with β-catenin signaling pathway in neural system. Additionally, knockout of PGRN leads to dramatically higher level of expression of β-catenin in primary murine chondrocytes (Zhao and Liu, unpublished data). In the present study, we observed that β-catenin was markedly elevated in IVD of PGRN−/− mice, followed by real-time PCR. (D) Increased expression of β-catenin in IVD of PGRN−/− mice, Total IVD protein extracts were collected from 3 mice of each group, and assayed by Western Blotting with anti-β-catenin, anti-β-tubulin (internal control) antibodies. (E) PGRN−/− mice revealed stronger β-catenin signal and the nuclear translocation (inserts) in IVD cells, determined by immunohistochemistry. IVD sections from 6-month old WT and PGRN−/− mice were stained with anti-β-catenin antibody (brown) and counterstained with methyl green (green). Representative pictures are shown. Scale bar, 50 μm. (F, G) Elevated mRNA levels of AXIN2, RUNX2 in IVD of PGRN−/− mice, measured by real-time PCR (n = 3, respectively). RNA was collected from IVD of 6-month WT and PGRN−/− mice, followed by real-time PCR. (H) A proposed model for explaining the protective role of PGRN in the course of IVD degeneration. The values are the mean ± SD of 3 independent experiments. *p < 0.05, ** p < 0.01 and *** p < 0.005 vs. WT group.

Figure 6 | Expressions of β-catenin and its target genes are enhanced in IVD of PGRN−/− mice. (A, B, C) Enhanced mRNA level of β-catenin in IVD of PGRN−/− mice, assayed by real-time PCR (n = 3, respectively). RNA was extracted from IVD of 4, 6, 9-month old WT and PGRN−/− mice, followed by real-time PCR. (D) Increased expression of β-catenin in IVD of PGRN−/− mice. Total IVD protein extracts were collected from 3 mice of each group, and assayed by Western Blotting with anti-β-catenin, anti-β-tubulin (internal control) antibodies. (E) PGRN−/− mice revealed stronger β-catenin signal and the nuclear translocation (inserts) in IVD cells, determined by immunohistochemistry. IVD sections from 6-month old WT and PGRN−/− mice were stained with anti-β-catenin antibody (brown) and counterstained with methyl green (green). Representative pictures are shown. Scale bar, 50 μm. (F, G) Elevated mRNA levels of AXIN2, RUNX2 in IVD of PGRN−/− mice, measured by real-time PCR (n = 3, respectively). RNA was collected from IVD of 6-month WT and PGRN−/− mice, followed by real-time PCR. (H) A proposed model for explaining the protective role of PGRN in the course of IVD degeneration. The values are the mean ± SD of 3 independent experiments. *p < 0.05, ** p < 0.01 and *** p < 0.005 vs. WT group.
β-catenin signaling pathway was also enhanced. Taken together, this implies that a protective role of PGRN in IVD may occur through interacting with the β-catenin signaling pathway. Collectively, PGRN plays an important role in maintaining the integrity of IVD during aging possibly by suppressing NF-κB signaling and β-catenin signaling pathways, which in turn prevents abnormal bone metabolism as well as degeneration of cartilage-like tissue in spine.

**Methods**

All the following methods were carried out in accordance with the approved guidelines.

**Mice.** All animal studies were performed in accordance with institutional guidelines and approval by the Institutional Animal Care and Use Committee of New York University. The generation and genotyping of PGRN deficient mice have been described previously17. 2-, 4-, 6- and 9-month old WT and PGRN−/− mice were used for these experiments.

**Immunohistochemistry.** Seventeen IVD samples from patients with disc degeneration were harvested with approval of Institutional Review Boards (IRB#2852 from Sutter Medical Center in California). Besides, IVD tissue from 2-, 4-, 6- and 9-month old WT mice were harvested and fixed in 4% PBS buffered paraformaldehyde at 4 °C overnight for immunohistochemistry. After the tissue was dehydrated and embedded in paraffin, 6-μm sections were cut. Thereafter, sections were deparaffinized by xylene immersion, rehydrated by graded ethanol, and treated with 0.1% trypsin for 30 minutes at 37 °C. After blocking in 20% goat serum for 60 minutes at room temperature, sections from human IVD were incubated with anti-PGRN polyclonal antibody (1:100 dilution; Santa Cruz Biotechnology), and sections from 6-month old mice were incubated with anti-neoepitope of aggrecan (1:100 dilution; Millipore, Cat. No: AB9135), anti-phosphorylated IκB-α (pIκB-α) (1:100 dilution; Santa Cruz Biotechnology; Cat. No. SC-101713) or anti-β-catenin monoclonal antibody (1:100 dilution; Santa Cruz Biotechnology; Cat. No. SC-1496) at 4 °C overnight, followed by incubation with a horseradish peroxidase–conjugated secondary antibody for 60 minutes at room temperature. The signal was detected using the Vector Elite ABC Kit (Vector; Santa Cruz Biotechnology).

**Histological scoring for degeneration of IVD.** The anatomy of IVD was instructed as previously reported49, and the degeneration of L3–L4 IVD was scored according to the classification system proposed by Boos et al.43 This was a classification system for grading the histological features of age-related changes in the lumbar disc. Histological gradings were performed separately on nucleus pulposus (NP; annulus fibrosus (AF), and endplate (EP). This classification system is based on an extensive semiquantitative histological analysis (NP/AF 0–22, EP 0–18, total 0–40). With this scoring system, a higher score indicates a more severe stage of disc degeneration. In this study we took 26 sections of WT mice (2-month old, n=8; 4-month old, n=8; 6-month old, n=6; 9-month old, n=6), and 32 sections of PGRN−/− mice (2-month old, n=8; 4-month old, n=8; 6-month old, n=6; 9-month old, n=10). The sections underwent double blind examinations by 2 authors independently (Y. Z. and B. R.).

**Micro-Ct.** Prior to histological processing, paraformaldehyde-fixed spines were micro-CT scanned with an Inveon scanner (Siemens Healthcare, Knoxville, TN, USA) and analyzed through structural reconstruction.

**Histological scoring for degeneration of IVD.** The degeneration of L3–L4 IVD was scored according to the classification system proposed by Boos et al.49 This was a classification system for grading the histological features of age-related changes in the lumbar disc. Histological gradings were performed separately on nucleus pulposus (NP), annulus fibrosus (AF), and endplate (EP). This classification system is based on an extensive semiquantitative histological analysis (NP/AF 0–22, EP 0–18, total 0–40). With this scoring system, a higher score indicates a more severe stage of disc degeneration. In this study, all the sections underwent double blind examinations by 2 authors independently (Y. Z. and B. R.).

**Western blot.** Total IVD extracts of indicated ages from WT and PGRN−/− mice were homogenized and proteins were collected. 3 mice of each group were used in this experiment. For each mouse, protein extracts from different IVD segments were collected together for Western blot. Proteins were resolved on a 10% SDS-polyacrylamide gel and electroblotted onto a nitrocellulose membrane. After blocking in 5% nonfat dry milk in Tris buffer-saline-Tween 20 (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.5% Tween 20), blots were incubated with polyclonal anti-PGRN, anti-phosphorylated IκB-α (pIκB-α) (1:100 dilution; Santa Cruz Biotechnology), and sections from indicated mice were incubated with anti-neoepitope of aggrecan (1:100 dilution; Millipore, Cat. No: AB9135), anti-phosphorylated IκB-α (pIκB-α) (1:100 dilution; Santa Cruz Biotechnology; Cat. No. SC-101713) or anti-β-catenin monoclonal antibody (1:100 dilution; Santa Cruz Biotechnology), and sections from indicated mice were incubated with horseradish peroxidase–conjugated secondary antibody for 60 minutes at room temperature. The signal was detected using the Vector Elite ABC Kit (Vector; Santa Cruz Biotechnology).
5. Yu, H. & Zhu, Y. Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervertebral disc. J Vet Med Sci 74, 9–15 (2012).
6. Gruber, H. E. et al. Constitutive expression of cathepsin K in the human intervertebral disc: new insight into disc extracellular matrix remodeling via cathepsin K and receptor activator of nuclear factor-kappaB ligand. Arthritis research & therapy 13, R40 (2011).
7. He, Z., Ong, C. H., Halper, J. & Bateman, A. Progranulin is a mediator of the wound response. Nat Med 9, 225–9 (2003).
8. Roughley, P. J. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine (Phila Pa 1976) 26, 2691–9 (2004).
9. Martens, L. H. et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest 122, 3955–9 (2012).
10. Liu, C. J. Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett 585, 3675–80 (2011).
11. Zhao, Y. P., Tian, Q. Y. & Liu, C. J. Progranulin deficiency exaggerates, whereas progranulin-derived Atsttrin attenuates, severity of dermatitis in mice. FEBS Lett 587, 1805–10 (2013).
12. Caroppo, P. et al. Extensive White Matter Involvement in Patients With Frontotemporal Lobar Degeneration: Think Progranulin. JAMA Neurol (2014) doi:10.1001/jamaneurol.2014.1316. [Epub ahead of print].
13. Wils, H. et al. Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol 228, 67–76 (2012).
14. Guo, F. et al. Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum 62, 2023–36 (2010).
15. Xu, K. et al. Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation. J Biol Chem 282, 11347–55 (2007).
16. Bai, X. H. et al. ADAMTS-7, a direct target of PTHR1, adversely regulates endochondral bone growth by associating with and inactivating GEP growth factor. Mol Cell Biol 29, 4201–19 (2009).
17. Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 323, 478–84 (2011).
18. Zhao, Y. P. et al. Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signaling. Ann Rheum Dis (2014) doi:10.1136/annrheumdis-2014-205779. [Epub ahead of print].
19. Zhao, Y., Liu, B. & Liu, C. J. Establishment of a surgically-induced model in mice to investigate the protective role of progranulin in osteoarthritis. J Vis Exp, e50924 (2014).
20. Boos, N. et al. Classification of age-related changes in lumbar intervertebral discs: 2002 Volvo Award in basic science. Spine (Phila Pa 1976) 27, 2631–44 (2002).
21. Tang, W. et al. The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice. Science 332, 478–484 (2011).
22. Huerta, K. et al. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976) 36, E1373–84 (2011).
23. Ellman, M. B. et al. Toll-like receptor adaptor signaling molecule MyD88 on intervertebral disk homeostasis: in vitro, ex vivo studies. Gene 505, 283–90 (2012).
24. Haynes, K. R. et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis research & therapy 14, R253 (2012).
25. Alquezar, C. et al. PGRN haploinsufficiency increased Wnt5α signaling in peripheral cells from frontotemporal lobar degeneration-progranulin mutation carriers. Neurobiol Aging 35, 866–98 (2014).
26. Rosen, E. Y. et al. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71, 1030–42 (2011).
27. Romanello, M. et al. Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment. Bone 58, 81–91 (2014).
28. Fukuta, S. et al. Abundance of calpain and aggrecan-cleavage products of calpain in degenerated human intervertebral discs. Osteoarthr Cartilage 19, 1254–62 (2011).
29. Gu, S. K. et al. MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc. Gene (2014) doi:10.1016/j.gene.2014.10.024. [Epub ahead of print].
30. McCann, M. R. et al. Acute vibration induces transient expression of anabolic genes in the murine intervertebral disc. Arthritis Rheum 65, 1853–64 (2013).
31. I llen-Junger, S. et al. Combined anti-inflammatory and anti-AGE drug treatments have a protective effect on intervertebral discs in mice with diabetes. PLoS One 8, e64302 (2013).
32. L iang, Q. Q. et al. The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. Bone 48, 1362–9 (2011).
33. Lotz, M. & Loeser, R. F. Effects of aging on articular cartilage homeostasis. Bone 51, 241–8 (2012).
34. Urban, J. P., Smith, S. & Fairbank, J. C. Nutrition of the intervertebral disc. Spine (Phila Pa 1976) 29, 2700–9 (2004).
35. Holm, S., Holm, A. K., Ekstrom, L., Karladani, A. & Hansson, T. Experimental disc degeneration due to endplate injury. J Spinal Disord Tech 17, 64–71 (2004).
36. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 10, 4025–31 (1991).
37. Druce, K. L., Jones, G. T., Macfarlane, G. J. & Basu, N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) (2014) [Epub ahead of print].
38. Erwin, W. M. & Fehlings, M. G. Intervertebral disc degeneration: genes hold the key. World Neurosurg 80, e313–3 (2013).
39. Liu, H. et al. LIM mineralization protein-1 suppresses TNF-alpha induced intervertebral disc degeneration by maintaining nucleus pulposus extracellular matrix production and inhibiting matrix metalloproteinase expressions. J Orthop Res (2014) doi:10.1002/jor.22732. [Epub ahead of print].
40. Siciliano, S. M. et al. Attenuation of inflammatory events in human intervertebral disc cells with a tumor necrosis factor antagonist. Spine (Phila Pa 1976) 36, 1190–6.
41. Tran, C. M. et al. CCN2 suppresses catabolic effects of interleukin-1beta through alphaVbeta1 and alphaVbeta3 integrins in nucleus pulposus cells: implications in intervertebral disc degeneration. J Biol Chem 289, 7374–87 (2014).
42. Tian, Y. et al. Inflammatory cytokines associated with degenerative disc disease control aggreganase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-kappab. Am J Pathol 182, 2310–21 (2013).
43. Wang, M. et al. Conditional activation of beta-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum 64, 2611–23 (2012).
44. Jin, H. et al. TGF-beta signaling plays an essential role in the growth and maintenance of intervertebral disc tissue. FEBS letters 585, 1209–15 (2011).
45. Wang, M. et al. Conditional activation of beta-catenin signaling leads to severe defects in intervertebral disc tissue. Arthritis Rheum 64, 2611–23 (2012).
46. Zhang, Y. et al. Histological features of endplates of the mammalian spine: from mice to men. Spine 39, E312–7 (2014).

Acknowledgments
We would like to thank Dr. Hee-Jeong Im Sampen for discussions and suggestions. This work was supported partly by NIH research grants R01AR062070, R01AR061484, R56AI109091, and a Disease Targeted Research Grant from Rheumatology Research Foundation (to C.J. Liu).

Author contributions
C.L. and T.J. designed the experiments; Y.Z. and B.L. Acquainted the data; Y.Z., Q.T., J.C. and B.R. Analysed and interpreted the data; Y.Z. did statistical analysis. All authors drafted and reviewed the manuscript.

Additional information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhao, Y. et al. Progranulin Knockout Accelerates Intervertebral Disc Degeneration in Aging Mice. Sci. Rep. 5, 9102; DOI:10.1038/srep09102 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/